Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Two cases of bisphosphonate-related osteonecrosis of the jaws are reported-one in the maxilla and the other in the mandible. The patients were treated with long-term antibiotics and minimal surgical debridement without major ablative surgery. Some clinical recommendations on prevention and management are suggested, as summarized from current literature.
Wong
Yiu-Kai
YK
Officer, Oral-Maxillofacial Surgery and Dental Unit, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. wykj@graduate.hku.hk
Cheng
Jason Chi-Fung
JC
D000368:Aged; D019386:Alendronate / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006931:Hyperbaric Oxygenation; D007093:Imidazoles / Q000009:adverse effects; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy; D014081:Tooth Extraction / Q000009:adverse effects; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate